Cbl-b checkpoint inhibitor (Apeiron)

N/A

Report date: 2025/03/14 16:34:49

Base Information

Drug NameCbl-b checkpoint inhibitor (Apeiron)
Drug Alias Namecasitas B cell lymphoma-b checkpoint inhibitor (Institute of Molecular Biotechnology/Medical University of Vienna)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionE3 ubiquitin-protein ligase CBL-B inhibitors
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustria
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedical University Of Vienna
China Registration ClassN/A

Develop Information

Active CompaniesApeiron Biologics
Inactive CompaniesIMBA - Institute of Molecular Biotechnology GmbHMedical University Of Vienna
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A